Navigation Links
Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Company's Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
Date:12/5/2012

e potential to significantly improve the way the disease is managed for these patients," said Robert Williamson, Chief Executive Officer.

BCI-632 increases synaptic glutamate by inhibiting the mGlu2/3 auto-receptor, which is located predominantly at the pre-synaptic site.  As in the case of ketamine, the long-lasting efficacy of BCI-632 can be blocked by either inhibition of AMPA receptors, mTOR or the BDNF signaling pathway.  In addition, BCI-632 also stimulates serotonin release and, after chronic dosing, hippocampal neurogenesis. 

 "BCI-838 is an oral prodrug for the active agent BCI-632 that is the leading mGluR2/3 antagonist in development," said John Hutchinson, Ph.D. Senior Vice President of Research.  "The successful completion of this Phase 1 trial, coupled with the encouraging qEEG data, offers promise that the drug will demonstrate efficacy in further clinical studies."

"BCI-838 may yield meaningful clinical benefits for patients suffering from TRD.  We believe that BCI-838 may generate early antidepressant responses similar to ketamine with a better safety profile and less adverse event liability.  Unlike ketamine, BCI-838 is an oral drug with no need for intravenous administration.  Furthermore, the neurogenic effect of BCI-838 in the hippocampus suggests that BCI-838 may be a novel treatment for a broader population of patients with mood or cognitive disorders," said Steven D. Targum. M.D., Chief Medical Officer.  "We look forward to the clinical advancement of this compound in a PoC study targeted for initiation in patients with TRD at the beginning of 2013."

About TRD and MDD

Major Depressive Disorder (MDD) is a highly prevalent disorder causing marked social and economic problems for affected patients and their families.  According to the World Health Organization, MDD is the leading cause of disability worldwide.  MDD is associated with high morbidity contr
'/>"/>

SOURCE BrainCells Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tria Beauty, Inc. Announces Partnership with Jenny McCarthy
2. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
3. UBM Canon Announces its New Medical Technology Seminar Series
4. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
5. Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
6. Ultra Clean Announces Participation in the Midtown CAP Summit Investor Conference
7. MetaStat Announces Presentations at the 2012 San Antonio Breast Cancer Symposium
8. Young Innovations Announces Definitive Agreement to be Acquired by Linden Capital Partners
9. ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
10. GDS International Announces "Industry Leader of the Year" Award at its Fourth Annual European Pharmaceutical Drug Discovery Summit
11. Elbit Imaging Ltd. Announces InSightecs ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the Brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Leading events organizer UBM ... for the seventh year to São Paulo, Brazil ... August 2014. The event will co-locate with Food Ingredients South ... comprehensive meeting point for the pharmaceutical industry.      ... for pharmaceutical sales are now exploring the South ...
(Date:7/25/2014)... BOHEMIA, N.Y. , July 25, 2014 /PRNewswire-iReach/ -- Dr. ... Pediatrics clinic, GPM Pediatrics, reacts to a recent study, ... adulthood. Photo - http://photos.prnewswire.com/prnh/20140723/129709 ... mothers exposed to severe stress are more likely than others ... occurred months before pregnancy." There were two specific ...
(Date:7/24/2014)... , July 24, 2014  PTC Therapeutics, Inc. ... Company will host a webcast conference call to report ... update on the company,s business and outlook on Thursday, ... opening of the market. The call ... (973) 935-8152 (international) five minutes prior to the start ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2
... 24, 2011 Reportlinker.com announces that a new market ... Therapeutics for Immune System Disorders ... the global market for drugs for the treatment of ... The market size is forecast to grow at a ...
... March 24, 2011 Tarsa Therapeutics today announced that ... salmon calcitonin in the treatment of postmenopausal osteoporosis was ...  The results will be used to support a New ... Administration (FDA) targeted for the fourth quarter of 2011, ...
Cached Medicine Technology:Reportlinker Adds Therapeutics for Immune System Disorders 2Reportlinker Adds Therapeutics for Immune System Disorders 3Reportlinker Adds Therapeutics for Immune System Disorders 4Reportlinker Adds Therapeutics for Immune System Disorders 5Reportlinker Adds Therapeutics for Immune System Disorders 6Reportlinker Adds Therapeutics for Immune System Disorders 7Reportlinker Adds Therapeutics for Immune System Disorders 8Reportlinker Adds Therapeutics for Immune System Disorders 9Reportlinker Adds Therapeutics for Immune System Disorders 10Reportlinker Adds Therapeutics for Immune System Disorders 11Reportlinker Adds Therapeutics for Immune System Disorders 12Reportlinker Adds Therapeutics for Immune System Disorders 13Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 2Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 3Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 4
(Date:7/25/2014)... (PRWEB) July 25, 2014 The European ... market in Europe with analysis and forecast of revenue. ... at $ 1007.2 million in 2013, and is estimated ... a CAGR of 9.4 %, from 2013 to 2018. ... chromatography reagents market, to get an idea of the ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- Although cervical cancers are ... linked to human papillomavirus (HPV) are increasing, a new ... the base of the tongue and tonsils have increased ... women younger than 45, the Canadian researchers report. ... among younger men and of anal cancer among younger ...
(Date:7/25/2014)... Innerspire, LLC ( http://www.innerspire.com ) announced today ... Creative Enrollment Specialist. In this role, Greg will be ... as his accomplished design skills to further develop Innerspire’s ... service the creative marketing needs of existing ... small business owners and individuals looking to accelerate the ...
(Date:7/25/2014)... 25, 2014 There are 700,000 people in ... each day. Though when someone hears the words, “you have ... unsure of the next step and where to turn. , ... out that next step by providing and pursuing the answers ... Brian Olson, member of the ABTA’s Board of Directors and ...
(Date:7/25/2014)... July 25, 2014 According to the ... Wafer, Devices, Applications, and Geography - Analysis & Forecast ... substrate is expected to reach $3.01 Billion by 2020 ... Technology Market for devices is expected to reach $6.17 ... includes an in-depth analysis of application and geography. , ...
Breaking Medicine News(10 mins):Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 2Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6
... for Prevention, Mental,Health and Low-Income Programs, Boosted ... Today a minority of,the U.S. Senate ... for the 44 million Americans who depend ... Providers Act, which would have improved,Medicare,s prevention, ...
... Would Have Improved Benefits for Prevention, Mental,Health and ... FE, N.M., June 12 SUMMARY: Today a,minority ... protect and,improve Medicare for the 44 million Americans ... and Providers Act, which would have,improved Medicare,s prevention, ...
... Corporation,(Nasdaq: PODD ), the leader in patch ... announced the Company will participate in,the William Blair ... scheduled to present an overview of the Company ... The Four Seasons Hotel in Chicago, IL., ...
... 12 Benchmark findings from the,study, conducted ... (BEB),suggest that formal management of training program ... one of the key success drivers in,effective ... Download a complimentary excerpt of this member-driven ...
... Senate voted 54,to 39 in favor of S. ... of 2008. However, that did not achieve the ... provisions that provide,prompt payment of Medicare Part D ... reimbursement cuts for generic prescription,drugs. In response Bruce ...
... complaints of insomnia predicted a healthier life, study finds ... is associated with healthy aging, a new study found. ... assessed 2,226 women aged 60 and older for use ... awakening, snoring, overall sleep quality, and sleep duration. Based ...
Cached Medicine News:Health News:AARP Indiana Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP Indiana Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:AARP NEW MEXICO KEY VOTE NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP NEW MEXICO KEY VOTE NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:Better Sleepers Are 'Successful Agers' 2
... range of automatic systems for performing erythrocyte ... of blood. With the introduction of the ... diagnostic market a truly revolutionary testing system ... associated with the traditional ESR techique.,By means ...
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
... VACUETTE® erythrocyte sedimentation rate analysers, ... The new generation unites the well-established ... whole range of additional innovations which ... erythrocyte sedimentation rate. Cost effectiveness is ...
Blood sedimentation rate analysis...
Medicine Products: